Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4407950 | 1.00 | BRD4 (0.38) | BRD4BRD2KMT2APIK3CDCRBN | |
| SCHEMBL15238061 | 0.78 | — | — | |
| SCHEMBL182572 | 0.71 | — | — | |
| SCHEMBL3043 | 0.69 | — | — | |
| SCHEMBL2398125 | 0.69 | BRD4 (0.43) | BRD4BRD2KMT2APIK3CDCRBN | |
| SCHEMBL717518 | 0.69 | BRD4 (0.43) | BRD4BRD2KMT2APIK3CDCRBN | |
| SCHEMBL735080 | 0.69 | — | — | |
| SCHEMBL556045 | 0.67 | — | — | |
| Water SCHEMBL3778195 | 0.67 | — | — | |
| Lithium SCHEMBL31009372 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026086923-A1 | PREPARATION METHOD FOR OLIGONUCLEOTIDE ANALOG | 福建盛迪医药有限公司 | 2026-04-30 | — | — | WO | claimed |
| US-20220056008-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VOXELOTOR | CRYSTAL PHARMA, S.A.U. (ES) | 2022-02-24 | — | — | US | claimed |
| EP-3898608-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VOXELOTOR | Crystal Pharma, S.A.U. (ES) | 2021-10-27 | — | — | EP | claimed |
| CN-113272290-A | Process and intermediates for synthesis of vortiotropium | 晶体制药独资有限公司 | 2021-08-17 | — | — | CN | claimed |
| EP-3299369-B1 | PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2020-11-11 | — | — | EP | claimed |
| WO-2020127945-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VOXELOTOR | BIONICE, S.L.U. (ES) | 2020-06-25 | — | — | WO | claimed |
| EP-3257855-B1 | METHOD FOR PREPARING IBRUTINIB | SHANGHAI DUDE MEDICAL SCIENCE AND TECH CO LTD (CN) | 2020-04-22 | — | — | EP | claimed |
| US-20180244667-A1 | PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2018-08-30 | — | — | US | claimed |
| EP-3299369-A1 | PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2018-03-28 | — | — | EP | claimed |
| US-20180044339-A1 | PROCESS FOR PREPARING IBRUTINIB | LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. (CN) | 2018-02-15 | — | — | US | claimed |
| EP-3257855-A1 | METHOD FOR PREPARING IBRUTINIB | Shanghai Dude Medical Science and Technology Co., Ltd. (CN) | 2017-12-20 | — | — | EP | claimed |
| WO-2026086923-A1 | PREPARATION METHOD FOR OLIGONUCLEOTIDE ANALOG | 福建盛迪医药有限公司 | 2026-04-30 | — | — | WO | disclosed |
| US-12492180-B2 | Process and intermediates for the preparation of Voxelotor | CURIA SPAIN, S.A.U. (ES) | 2025-12-09 | — | — | US | disclosed |
| US-20250260735-A1 | CONTAINER IMAGE STREAMING AMONG PEERS IN A DYNAMICALLY SCALABLE P2P CLUSTER | MICROSOFT TECHNOLOGY LICENSING, LLC | 2025-08-14 | — | — | US | disclosed |
| CN-114539133-B | Method for preparing prucalopride intermediate 1- (3-methoxypropyl) -4-piperidinamine | 鲁南制药集团股份有限公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20180244667-A1 | PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2018-08-30 | — | — | US | disclosed |
| EP-3299369-A1 | PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2018-03-28 | — | — | EP | disclosed |
| US-20180044339-A1 | PROCESS FOR PREPARING IBRUTINIB | LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. (CN) | 2018-02-15 | — | — | US | disclosed |
| EP-3257855-A1 | METHOD FOR PREPARING IBRUTINIB | Shanghai Dude Medical Science and Technology Co., Ltd. (CN) | 2017-12-20 | — | — | EP | disclosed |
| US-20090318720-A1 | Process for selectively synthesising 3 alpha-hydroxychlormadinone acetate | GRUNENTHAL GMBH (DE) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044339-A1 | PROCESS FOR PREPARING IBRUTINIB | BTK, SYK, ABL1 | BRD4 851/4885BRD2 992/4885KMT2A 2056/4885 |
| US-20220056008-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF VOXELOTOR | VAT1, VPS51, VMP1 | BRD4 1892/4885BRD2 3207/4885KMT2A 3145/4885 |
| US-20180244667-A1 | PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | MET, MERTK, DMPK | BRD4 1498/4885BRD2 1352/4885KMT2A 885/4885 |
| US-20090318720-A1 | Process for selectively synthesising 3 alpha-hydroxychlormadinone acetate | CYP51A1, HSD17B7, HSD17B13 | BRD4 2614/4885BRD2 1755/4885KMT2A 473/4885 |
| US-12492180-B2 | Process and intermediates for the preparation of Voxelotor | VPS51, KIF15, VAT1 | BRD4 3222/4885BRD2 4157/4885KMT2A 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.